

Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Non-Hodgkin Lymphoma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following best describes 5-year efficacy findings with tafasitamab and lenalidomide for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in the Phase II L-MIND trial?
 - a. Objective response rate (ORR) 17% with no complete responses (CRs)
 - b. ORR ~37% with 10% CRs
 - c. ORR ~57% with >40% CRs
2. In the Phase III STARGLO trial, the combination of glofitamab and gemcitabine/oxaliplatin resulted in which of the following outcomes in comparison to rituximab with gemcitabine/oxaliplatin for patients with transplant-ineligible R/R DLBCL?
 - a. Inferior overall survival (OS)
 - b. Noninferior OS
 - c. Significantly improved OS
3. Which of the following efficacy findings was observed in previously untreated mantle cell lymphoma in patients who received the Bruton tyrosine kinase inhibitor-containing regimen compared to chemoimmunotherapy alone in the recently reported Phase III ECHO trial?
 - a. A detrimental OS trend
 - b. A favorable OS trend
 - c. OS data were not reported in the recent presentation
4. What is the mechanism of action of golcadomide?
 - a. BTK inhibitor
 - b. AKT inhibitor
 - c. CD19-directed immunotherapy
 - d. CELMoD
5. Which of the following best represents results of a Phase II single-center study of loncastuximab tesirine in combination with rituximab for patients with R/R follicular lymphoma?
 - a. 12-month progression-free survival (PFS) rate of 25% with favorable toxicity profile
 - b. 12-month PFS rate of 50% with significant tolerability issues
 - c. 12-month PFS rate of ~75% with significant tolerability issues
 - d. 12-month PFS rate >90% with favorable toxicity profile